The Mechanism of Action and Toxicity Profile of Duvelisib (IPI-145)
Ian W. Flinn, MD, PhD, discusses the mechanism of action and toxicity profile of duvelisib (IPI-145). Duvelisib is being studied for the treatment of hematologic malignancies.
Clinical Pearls
Ian W. Flinn, MD, PhD, director, Hematologic Malignancies Research Program, Sarah Cannon Research Institute, discusses the mechanism of action and toxicity profile of duvelisib (IPI-145). Duvelisib is being studied for the treatment of hematologic malignancies.
- Duvelisib inhibits both delta and gamma isoform.
- The hope is that the molecule targets both the tumor cell as well as the microenvironment.
- The toxicity profile of duvelisib is still being studied.
- To date, the molecule appears to have a similar toxicity profile of other PI3K inhibitors.
Recent Videos
Related Content
Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond
March 21st 2025Article
Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.
Read More
